Dr Reddys Laboratories (RDY)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and int...
- Open
- 12.180
- High
- 12.235
- Low
- 12.130
- Prev. Close
- 12.220
- Volume
- 1.55M
- Turnover
- 18.88M
- Avg Price
- 12.170
- Bid/Ask Ratio
- 8.68%
- Amplitude
- 0.86%
- 52wk High
- 15.559
- Volume Ratio
- 0.39
- Turnover Ratio
- 0.26%
Dr Reddys Laboratories Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$13.4810.88%
Forecast & RatingHold
5analysts
- Strong buy40.00%
- Buy0.00%
- Hold40.00%
- Sell20.00%
- Strong sell0.00%
News
- Tip Ranks · 1 day ago, 01:27 PM
Dr. Reddy’s Laboratories Allots New Shares Under Employee Stock Option Scheme
- PUBT · Aug 17 at 05:41 AM
Dr Reddy’s gets four USFDA observations at Bachupally formulations plant after GMP inspection
- PUBT · Aug 13 at 08:56 AM
Dr. Reddy’s API and Services CEO Deepak Sapra resigns, set to exit in November
- Market Beat · Aug 12 at 05:42 AM
Zacks Research Issues Optimistic Forecast for RDY Earnings
- PUBT · Aug 11 at 07:20 AM
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases
- Tip Ranks · Aug 10 at 11:48 AM
Dr. Reddy’s Ends Novartis India Brand Distribution Pact, Plans Transition by September 2026
